Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Denmark.
Psychiatric Center Copenhagen, Denmark.
Int J Neuropsychopharmacol. 2023 Sep 25;26(9):639-648. doi: 10.1093/ijnp/pyad041.
A prominent finding in major depressive disorder (MDD) is distorted stress hormone dynamics, which is regulated by serotonergic brain signaling. An interesting feature of the cerebral serotonin system is the serotonin 4 receptor (5-HT4R), which is lower in depressed relative to healthy individuals and also has been highlighted as a promising novel antidepressant target. Here, we test the novel hypothesis that brain 5-HT4R availability in untreated patients with MDD is correlated with cortisol dynamics, indexed by the cortisol awakening response (CAR). Further, we evaluate if CAR changes with antidepressant treatment, including a selective serotonin reuptake inhibitor, and if pretreatment CAR can predict treatment outcome.
Sixty-six patients (76% women) with a moderate to severe depressive episode underwent positron emission tomography imaging with [11C]SB207145 for quantification of brain 5-HT4R binding using BPND as outcome. Serial home sampling of saliva in the first hour from awakening was performed to assess CAR before and after 8 weeks of antidepressant treatment. Treatment outcome was measured by change in Hamilton Depression Rating Scale 6 items.
In the unmedicated depressed state, prefrontal and anterior cingulate cortices 5-HT4R binding was positively associated with CAR. CAR remained unaltered after 8 weeks of antidepressant treatment, and pretreatment CAR did not significantly predict treatment outcome.
Our findings highlight a link between serotonergic disturbances in MDD and cortisol dynamics, which likely is involved in disease and treatment mechanisms. Further, our data support 5-HT4R agonism as a promising precision target in patients with MDD and disturbed stress hormone dynamics.
重度抑郁症(MDD)的一个突出表现是应激激素动力学的扭曲,而这是由血清素能的大脑信号调节的。大脑血清素系统的一个有趣特征是 5-羟色胺 4 受体(5-HT4R),与健康个体相比,抑郁患者的 5-HT4R 水平较低,并且也被强调为有前途的新型抗抑郁药靶标。在这里,我们检验了一个新的假设,即未经治疗的 MDD 患者大脑中的 5-HT4R 可用性与皮质醇动力学(以皮质醇觉醒反应(CAR)为指标)相关。此外,我们评估了 CAR 是否随抗抑郁治疗而改变,包括选择性 5-羟色胺再摄取抑制剂,以及 CAR 是否可以预测治疗结果。
66 名(76%为女性)中度至重度抑郁发作的患者接受了[11C]SB207145 的正电子发射断层扫描成像,以 BPND 作为脑 5-HT4R 结合的量化结果。在接受抗抑郁治疗 8 周之前和之后,对第一个小时内从醒来开始的唾液进行了连续的家庭采样,以评估 CAR。治疗结果通过汉密尔顿抑郁量表 6 项的变化来衡量。
在未用药的抑郁状态下,前额叶和前扣带回皮质的 5-HT4R 结合与 CAR 呈正相关。抗抑郁治疗 8 周后,CAR 没有改变,并且 CAR 预处理不能显著预测治疗结果。
我们的研究结果强调了 MDD 中的血清素紊乱与皮质醇动力学之间的联系,这可能涉及到疾病和治疗机制。此外,我们的数据支持 5-HT4R 激动剂作为伴有应激激素动力学紊乱的 MDD 患者的一个有前途的精准治疗靶点。